$0.28
+0.01 (+5.02%)
Open$0.27
Previous Close$0.27
Day High$0.29
Day Low$0.26
52W High$2.89
52W Low$0.21
Volume—
Avg Volume1.86M
Market Cap7.99M
P/E Ratio—
EPS$-7.39
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+7,670.7% upside
Current
$0.28
$0.28
Target
$22.10
$22.10
$15.13
$22.10 avg
$31.02
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.53M | 1.79M | 1.31M |
| Net Income | -242,271,633 | -255,142,136 | -292,011 |
| Profit Margin | -15,861.4% | -15,068.3% | -22.2% |
| EBITDA | -201,812,489 | -224,341,053 | -341,169 |
| Free Cash Flow | — | — | -173,511 |
| Rev Growth | -14.5% | -14.5% | +20.5% |
| Debt/Equity | — | — | 0.83 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |